Rating Change
Raymond James analysts initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a rating of Market Perform on October 09, 2026.
new coverageNASDAQ:NKTR
Raymond James Initiates Coverage on Nektar Therapeutics (NKTR) with Market Perform
Raymond James analysts initiated coverage on Nektar Therapeutics (NASDAQ:NKTR) with a rating of Market Perform on October 09, 2026.
At publication ·
What changed
Nektar Therapeutics (NASDAQ:NKTR) · new coverage
- Firm
- Raymond James
- Rating
- Market Perform
- Price at event
- $41.17
- Market capitalization
- $1.0B
At a glance
Key takeaways
- Raymond James initiated coverage of Nektar Therapeutics with a Market Perform rating on October 09, 2026.
- Nektar Therapeutics trades at $41.17 with a $1.0 billion market capitalization in the healthcare sector.
Market Context
Nektar Therapeutics operates in the Healthcare sector. The stock currently trades at $41.17 with a market capitalization of $1.0B.
Analyst coverage from Raymond James provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Nektar Therapeutics.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Nektar Therapeutics
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 09, 2026 | BTIG | Buy | N/A |
| Oct 09, 2026 | Raymond James | Market Perform | N/A |
| Oct 02, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 28, 2026 | BTIG | Buy | N/A |
| Sep 25, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View NKTR Stock Page
Frequently Asked Questions
What does the Market Perform rating mean for NKTR?
A rating of Market Perform from Raymond James reflects the analyst's outlook on Nektar Therapeutics (NASDAQ:NKTR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the NKTR forecast page.